
Head of Bioprocessing at Merck Life Science India discusses how the COVID-19 pandemic accelerated vaccine development and transformed drug development. Collaboration among regulators, government bodies, investigators, and scientists expedited the clinical to-commercialization process. Supply chain challenges were highlighted, leading to streamlining and predictive optimization efforts. mRNA technology in COVID-19 vaccines shows promise for post-pandemic breakthroughs. Lessons include the importance of collaboration, agility, and preparedness for future crises in the pharmaceutical industry.
Like
Save
Share